Kolexia
Abraham Christine Oncologie médicale
Abraham Christine
Oncologie médicale
Hôpital Foch
Suresnes, France
39 Activités
35 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs du testicule Séminome Tumeurs du pancréas Carcinomes Carcinome transitionnel Tumeurs du sein Tumeurs de la vessie urinaire {{person.topmesh10.name}}

Collaborateurs

Voir plus
Geay Jean-Francois
Geay Jean-Francois
Centre hospitalier de Versailles, Le Chesnay, France
Billard David
Billard David
Hôpital Foch, Suresnes, France
Benmaziane-Teillet Asmahane
Benmaziane-Teillet Asmahane
Hôpital Foch, Suresnes, France
Vitu-Loas Laurence
Vitu-Loas Laurence
Centre De Radiologie Et De Traitement Des Tumeurs, Versailles, France

Industries

Voir plus
Ipsen
5 collaboration(s)
Dernière en 2022
Servier
4 collaboration(s)
Dernière en 2023
Pfizer
4 collaboration(s)
Dernière en 2022
Merck-Serono
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Toxicités cutanées et efficacité de l’enfortumab vedotin. Expérience monocentrique en vie réelle
116e congrès français d'urologie   01 novembre 2022
1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
European urology   20 mai 2022
Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Current oncology (Toronto, Ont.)   10 février 2022
Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis.
2020 Genitourinary Cancers Symposium   19 février 2020
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
JAMA oncology   10 février 2020
KALICOU3: Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer
Essai Clinique (Centre Oscar-Lambret)   24 juin 2019
Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
SEMITEP: Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma
Essai Clinique (Gustave-Roussy)   08 juin 2016
Preoperative Diagnostic Angiogram and Endovascular Aortic Stent Placement for Appleby Resection Candidates: A Novel Surgical Technique in the Management of Locally Advanced Pancreatic Cancer.
HPB surgery : a world journal of hepatic, pancreatic and biliary surgery   28 septembre 2015